Evidence map›Paper›PMID 42204923›Full record

ArticleFuture oncology (London, England)2026

Safety of fruquintinib mono- and combo therapy in metastatic colorectal cancer: real-world subgroup analysis from China.

Zhiqiang Wang, Haijun Zhong, Yifu He, Chen Zhang, Zuoxing Niu, Shujun Yang, Tao Zhang, Liangjun Zhu, Yongqian Shu, Jianjun Peng and 15 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Future oncology (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Zhiqiang WangState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China.
Haijun ZhongDepartment of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, China.
Yifu HeDepartment of Medical Oncology, Anhui Provincial Cancer Hospital, Hefei, China.
Chen ZhangDepartment of Radiotherapy and Chemotherapy, Ningbo No.2 Hospital, Ningbo, China.
Zuoxing NiuDepartment of Medical Oncology, Shandong Cancer Hospital, Shandong Academy of Medical Sciences, Jinan, China.
Shujun YangDepartment of Internal Medicine, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China.
Tao ZhangCancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Liangjun ZhuDepartment of Medical Oncology, Jiangsu Cancer Hospital, Nanjing, China.
Yongqian ShuDepartment of Medical Oncology, Jiangsu Province Hospital and Nanjing Medical University First Affiliated Hospital, Nanjing, China.
Jianjun PengCenter of Gastrointestinal Surgery, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Yan SongDepartment of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Jian LiDepartment of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing, China.
Ying YuanDepartment of Medical Oncology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Haibo ZhangGuangdong Provincial Hospital of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong Provincial Academy of Chinese Medical Sciences, Guangzhou, China.
Gengsheng YuDepartment of Medical Oncology, Jiangmen Central Hospital, Jiangmen, China.
Yunqi HuaDepartment of Medical Oncology, Baotou Cancer Hospital, Baotou, China.
Jianjun XiaoDepartment of Oncology, Zhongshan City People's Hospital, Zhongshan, China.
Jianfei FuDepartment of Medical Oncology, Jinhua Central Hospital, Jinhua, China.
Yulong ZhengDepartment of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Jingyu ZhuHUTCHMED Limited, Shanghai, China.
Hua XueHUTCHMED Limited, Shanghai, China.
Xian LuoHUTCHMED Limited, Shanghai, China.
Weiguo SuHUTCHMED Limited, Shanghai, China.
Shukui QinGastrointestinal Cancer Center of Nanjing Tianyinshan Hospital, China Pharmaceutical University, Nanjing, China.
Jin LiDepartment of Oncology, Shanghai GoBroad Cancer Hospital, China Pharmaceutical University, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFruquintinib, a highly selective vascular endothelial growth factor receptor 1, 2, 3 inhibitors, has demonstrated significant efficacy in phase III trials for metastatic colorectal cancer (mCRC). However, real-world evidence is essential to confirm its safety profile across diverse treatment settings.

aimThis subgroup analysis of a phase IV study aims to evaluate the safety of fruquintinib both as monotherapy and combination therapy in a real-world setting.

methodsPhase IV-study data were categorized by treatment regimen into fruquintinib monotherapy and combination therapy groups. Safety profiles including TEAEs and TRAEs were recorded.

resultsOverall, 2798 patients were enrolled in the phase IV study (2019-2022) and received fruquintinib 5 mg/day or per physician's choice. Among them, 1888 patients received monotherapy, whereas 775 patients received combination therapy: fruquintinib + chemotherapy (

conclusionFruquintinib combination therapy demonstrated a satisfactory safety profile within the treatment groups.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBenzofuransColorectal NeoplasmsProtein Kinase InhibitorsQuinazolinesAdultAgedAged, 80 and overChinaFemaleHumansMaleMiddle AgedNeoplasm MetastasisBenzofuransHMPL-013Protein Kinase InhibitorsQuinazolinesColorectal cancercombination therapyfruquintinibsafetythird-line treatment

Identifiers

PMID42204923
PMCPMC13228932

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.